Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.66 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.66 |
| ▸ | CDK2 | P24941 | 11/20 | 0.61 |
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 11/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 11/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.51 |
| ▸ | BRAF | P15056 | 2/20 | 0.49 |
| ▸ | MGMT | P16455 | 4/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2,6-Diaminopurine SCHEMBL24053 | 0.79 | PDPK1 (1.00) | PDPK1GDACDK2DPP4MAP3K5 | |
| SCHEMBL2526552 | 0.79 | PDPK1 (0.44) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL28206545 | 0.78 | PDPK1 (0.96) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL8757979 | 0.78 | PDPK1 (0.96) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL27891733 | 0.78 | PDPK1 (0.96) | PDPK1GDACDK2DPP4MAP3K5 | |
| Thioguanine SCHEMBL183648 | 0.76 | PDPK1 (0.66) | PDPK1GDACDK2DPP4MAP3K5 | |
| SCHEMBL135690 | 0.76 | CDK2 (1.00) | PDPK1GDACDK2DPP4MAP3K5 | |
| 6-Chloroguanine SCHEMBL64059 | 0.76 | DPP4 (1.00) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL29143272 | 0.76 | PDPK1 (0.92) | PDPK1GDACDK2DPP4MAP3K5 | |
| SCHEMBL355362 | 0.76 | PDPK1 (0.66) | PDPK1GDACDK2DPP4MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490368-B1 | 2,2-BIS(HYDROXYMETHYL)CYCLOPROPYLIDENEMETHYL - PURINES AND -PYRIMIDINES AS ANTIVIRAL AGENTS | UNIV WAYNE STATE (US) | 2011-08-03 | — | — | EP | claimed |
| US-7393855-B2 | 2,2-bis-(hydroxymethyl)cyclopropylidenemethyl-purines and pyrimidines as antiviral agents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-07-01 | — | — | US | claimed |
| EP-1490368-A4 | 2,2-BIS(HYDROXYMETHYL)CYCLOPROPYLIDENEMETHYL - PURINES AND -PYRIMIDINES AS ANTIVIRAL AGENTS | UNIV WAYNE STATE (US) | 2006-07-19 | — | — | EP | claimed |
| US-20050113393-A1 | 2,2-bis-(hydroxymethyl)cyclopropylidenemethyl-purines and pyrmindines as antiviral agents | WAYNE STATE UNIVERSITY (US) | 2005-05-26 | — | — | US | claimed |
| EP-1490368-A2 | 2,2-BIS(HYDROXYMETHYL)CYCLOPROPYLIDENEMETHYL - PURINES AND -PYRIMIDINES AS ANTIVIRAL AGENTS | Wayne State University (US) | 2004-12-29 | — | — | EP | claimed |
| WO-2003104440-A2 | 2,2-BIS(HYDROXYMETHYL)CYCLOPROPYLIDENEMETHYL - PURINES AND -PYRIMIDINES AS ANTIVIRAL AGENTS | WAYNE STATE UNIVERSITY (US) | 2003-12-18 | — | — | WO | claimed |
| US-5817799-A | 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-10-06 | — | — | US | claimed |
| EP-0540686-B1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1995-08-30 | — | — | EP | claimed |
| EP-0540686-A4 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1993-05-26 | — | — | EP | claimed |
| EP-0540686-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES. | US COMMERCE (US) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001700-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-02-06 | — | — | WO | claimed |
| US-20220033432-A1 | ANTI-HEPATITIS B VIRUS AGENT | DAIKIN INDUSTRIES, LTD. (JP) | 2022-02-03 | — | — | US | disclosed |
| EP-3939655-A1 | ANTI-HEPATITIS B VIRUS AGENT | DAIKIN INDUSTRIES, LTD. (JP) | 2022-01-19 | — | — | EP | disclosed |
| WO-2020184677-A1 | ANTI-HEPATITIS B VIRUS AGENT | ダイキン工業株式会社 | 2020-09-17 | — | — | WO | disclosed |
| CN-1738829-B | New 2',5'-oligoadenylic acid analog | SANKYO CO | 2012-11-28 | — | — | CN | disclosed |
| WO-2003104440-A2 | 2,2-BIS(HYDROXYMETHYL)CYCLOPROPYLIDENEMETHYL - PURINES AND -PYRIMIDINES AS ANTIVIRAL AGENTS | WAYNE STATE UNIVERSITY (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003104440-A2 | 2,2-BIS(HYDROXYMETHYL)CYCLOPROPYLIDENEMETHYL - PURINES AND -PYRIMIDINES AS ANTIVIRAL AGENTS | WAYNE STATE UNIVERSITY (US) | 2003-12-18 | — | — | WO | disclosed |
| EP-0544668-A1 | -6-FLUORO-9-(2,3-DIDEOXY-B-D-GLYCERO-PENTOFURANOSYL)-9H-PURINES AND THEIR USE ASANTIVIRAL AGENTS | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE (US) | 1993-06-09 | — | — | EP | disclosed |
| EP-0544668-A4 | 6-HALO- AND 2-AMINO-6-HALO-PURINE 2',3'-DIDEOXY NUCLEOSIDES AND THEIR USE AS ANTIVIRAL AGENTS. | US SECRETARY UNITED STATES DEP (JP) | 1993-03-03 | — | — | EP | disclosed |
| WO-1991012260-A1 | 6-HALO- AND 2-AMINO-6-HALO-PURINE 2',3'-DIDEOXY NUCLEOSIDES AND THEIR USE AS ANTIVIRAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033432-A1 | ANTI-HEPATITIS B VIRUS AGENT | SLC10A1, HAVCR2, FABP1 | PDPK1 4788/4885GDA 397/4885CDK2 1288/4885 |
| US-20050113393-A1 | 2,2-bis-(hydroxymethyl)cyclopropylidenemethyl-purines and pyrmindines as antiviral agents | TPMT, HPRT1, MTAP | PDPK1 3602/4885GDA 76/4885CDK2 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.